Drug Trial Radar · NCT07014826
A Trial of HRS-5965 Capsule in Primary IgA Nephropathy
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
389
Actual
Start
Jun 4, 2025
Primary completion
Oct 2027
Study completion Dec 2028
Sponsor
- Lead sponsor
- Chengdu Suncadia Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This multicenter, randomized, double-blind, parallel, placebo-controlled study is being conducted to evaluate the efficacy, and safety of HRS-5965 capsule for primary IgA nephropathy.
Conditions
- Primary IgA Nephropathy
Interventions
HRS-5965Drug
HRS-5965
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ratio of 24-hour Urinary protein to creatinine ratio (UPCR) to baselineTime frame: Baseline and Week 36
- The total annualized slope of estimated glomerular filtration rate(eGFR)Time frame: Baseline and Week 104
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.